Arcutis Biotherapeutics Upgraded by Mizuho Securities
Arcutis Biotherapeutics Inc. saw its stock rise 6% in after-hours trading after Mizuho Securities upgraded its rating on the company to Buy. Mizuho also set a price target of $8.00, indicating further upside potential for the stock. This upgrade comes as a positive sign for Arcutis, a biopharmaceutical company focused on developing innovative treatments for various skin diseases. Investors appear to be optimistic about the company’s pipeline and the potential for its products to gain regulatory approval and generate revenue in the future.
Exclusive Access: Unlock Premium, Confidential Insights
Unlock This Exclusive Content—Subscribe Instantly!
Login if you have purchased
